Independent research groups outside the original Sikiric-Seiwerth laboratory have published on the musculoskeletal soft-tissue findings, providing cross-laboratory replication of the core repair-model claims (PMID 30915550)
It should be viewed as complementary, not a substitute for medical treatment
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Finally, you choose the intended dose per injection
This is where we review your medical history, discuss your injury or condition, determine if BPC-157 is appropriate, and build your dosing protocol